October 2020 Question of the Month

What change do you most expect to see in the 340B program in the next year?

Reduced drug sales at 340B prices: 60%

Legislative changes to 340B program: 20%

HRSA lawsuit challenging 340B sales limitations by manufacturers: 20%

Shifting drug sales to 340B supportive manufacturers: 0%